MedTrace Logo

Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)

NCT03322319 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2017-10-27

No results posted yet for this study

Summary

The frequency of cardiac amyloidosis among patients presenting with a so-called left ventricular hypertrophy remains unknown. This problem is especially relevant in the Caribbean's, where an amyloidosis-prone mutation of transthyretin gene might be frequent.

Conditions

  • Left Ventricular Hypertrophy

Interventions

PROCEDURE

Tissue biopsies

It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment. Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB).

Sponsors & Collaborators

  • University Hospital Center of Martinique

    lead OTHER

Principal Investigators

  • Jocelyn INAMO, MD-PhD · Centre Hospitalier Universitaire de Martinique, France

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-23
Primary Completion
2015-12-02
Completion
2016-01-18

Countries

  • Guadeloupe
  • Martinique

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322319 on ClinicalTrials.gov